Sign in

    Nick Lorusso

    Research Analyst at TD Cowen

    Nick Lorusso is an Equity Research Associate at TD Cowen, specializing in biotechnology with a focus on therapeutic areas such as obesity and metabolic diseases. He has contributed to research covering innovative companies engaged in myostatin and activin inhibitor development, and is actively involved in proprietary industry analysis that supports senior analysts in delivering actionable investment recommendations. Lorusso began his analyst career at Cowen and transitioned to TD Cowen (TD Securities USA) in 2024, playing a key role in multi-analyst research reports and sector evaluations. He holds FINRA securities licenses appropriate for his research role and has developed expertise in synthesizing both expert and KOL insights into company and product evaluation.

    Nick Lorusso's questions to Telix Pharmaceuticals (TLX) leadership

    Nick Lorusso's questions to Telix Pharmaceuticals (TLX) leadership • H1 2025

    Question

    Nick Lorusso, on behalf of Tara Bancroft at TD Cowen, questioned the drivers behind the 2025 revenue guidance, asking if slowing Elucix sales growth was due to the loss of pass-through status and if Gozelix could reignite growth.

    Answer

    Group CEO Christian Behrenbruch stated that despite Elucix losing pass-through status, dose volumes grew 7% quarter-over-quarter. He explained that the company took specific commercial actions to stabilize its customer base ahead of Gozelix gaining reimbursement in Q4, which is a key part of their differentiated growth strategy. Kevin Richardson, CEO of Telix Precision Medicine, added that the sales team continues to focus on the product's clinical accuracy and reliability.

    Ask Fintool Equity Research AI

    Nick Lorusso's questions to IOVANCE BIOTHERAPEUTICS (IOVA) leadership

    Nick Lorusso's questions to IOVANCE BIOTHERAPEUTICS (IOVA) leadership • Q2 2025

    Question

    Nick Lorusso, on for Tyler Van Buren at TD Cowen, asked for an update on how Amtagvi infusions are tracking quarter-to-date and requested new metrics on ATC prescribing depth, such as the percentage of centers that have infused one or more patients.

    Answer

    Chief Commercial Officer Dan Kirby stated that while demand remains strong, it is company policy not to comment on intra-quarter infusion numbers. He confirmed that prescribing depth at ATCs has increased but noted that the company would no longer provide specific metrics on the percentage of centers hitting certain infusion thresholds.

    Ask Fintool Equity Research AI